Key Findings Indicate a Dual Impact on Cardiovascular Health

The study, conducted by researchers at the University of Chicago using the Merative MarketScan Commercial Database, analyzed a significant cohort of 3,786 adults who underwent HGNS implantation between 2015 and 2024. These patients were meticulously matched with 3,395 individuals who met the candidacy criteria for HGNS—meaning they had a diagnosed moderate to severe OSA confirmed by a sleep study and demonstrated non-adherence to positive airway pressure (PAP) therapy—but had not received the implant. The matching process employed propensity score matching to account for a wide array of baseline characteristics, including demographics, existing comorbidities, cardiovascular history, duration of confirmed OSA, and the year of their index event.

The findings reveal a nuanced picture regarding the incidence of cardiovascular disease (CVD) and related conditions. Over a two-year follow-up period, HGNS was associated with a lower hazard of developing new-onset diabetes in patients who did not have pre-existing diabetes (Hazard Ratio [HR] 0.19; 95% Confidence Interval [CI] 0.09 to 0.38 after two years). Similarly, for hypertension, HGNS showed a lower hazard of diagnosis after the initial two-year period in this same subgroup (HR 0.49; 95% CI 0.33 to 0.73). This suggests that HGNS may, over time, contribute to better management or prevention of these critical metabolic and vascular conditions.

However, the initial two years post-implantation presented a different scenario. The study found that HGNS was associated with a higher hazard of developing hypertension within the first two years among patients without pre-existing CVD (HR 1.70; 95% CI 1.26 to 2.28). More concerningly, for patients who already had baseline diabetes or hypertension, HGNS was linked to higher hazards of both minor cardiovascular events (defined as cardiac arrhythmia or coronary artery disease) (HR 1.44; 95% CI 1.06 to 1.95) and major cardiovascular events (defined as cerebrovascular disease, heart failure, or myocardial infarction) (HR 1.62; 95% CI 1.06 to 2.48) within the first two years.

After the two-year mark, the hazard ratios for minor and major cardiovascular events in the overall HGNS group did not reach statistical significance (minor HR 0.60; 95% CI 0.35 to 1.04; major HR 0.65; 95% CI 0.31 to 1.36). However, time-varying models, which assess the evolving risk over time, indicated decreasing trends in the hazards of both minor (HR 0.42; 95% CI 0.22 to 0.79) and major (HR 0.40; 95% CI 0.17 to 0.93) cardiovascular events after the initial two-year period. This observation strongly supports the notion of a potential, albeit delayed, protective effect of HGNS on cardiovascular outcomes.

Understanding the Context: The Pervasive Impact of Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is far from a benign condition; it is a highly prevalent disorder in the United States, affecting millions of individuals. Its impact extends significantly beyond disrupted sleep, posing a substantial threat to cardiovascular health. Untreated OSA is a well-established risk factor for a cascade of serious cardiovascular complications, including atrial fibrillation, stroke, heart failure, coronary artery disease, myocardial infarction, and ultimately, increased mortality.

The primary and most widely recommended treatment for OSA is positive airway pressure (PAP) therapy, which involves wearing a mask that delivers pressurized air to keep the airway open during sleep. While effective, PAP therapy suffers from a critical limitation: poor long-term adherence. Many patients find the mask uncomfortable, experience claustrophobia, or struggle with the noise, leading to inconsistent or abandoned use. This lack of adherence leaves a significant portion of the OSA population vulnerable to its severe health consequences.

Hypoglossal nerve stimulation (HGNS) emerged as a promising alternative for individuals who cannot tolerate or achieve adequate control with PAP. Approved by the U.S. Food and Drug Administration (FDA), HGNS involves surgically implanting a device that stimulates the hypoglossal nerve, which controls the tongue. By stimulating this nerve, the tongue is gently moved forward during sleep, preventing airway collapse. Clinical trials have demonstrated that HGNS can significantly improve the apnea-hypopnea index (AHI)—a measure of sleep apnea severity—and lead to better patient-reported outcomes, including improved sleep quality and daytime alertness. However, the long-term cardiovascular effects of this treatment have remained an area of ongoing investigation.

A Deeper Dive into the Study Design and Data

The retrospective cohort study utilized the Merative MarketScan Commercial Database, a vast repository of healthcare claims data from a large U.S. commercial insurance population spanning from 2015 to 2024. This dataset allowed researchers to observe the real-world experiences of a substantial number of patients undergoing HGNS.

The study meticulously defined its patient cohorts. The HGNS group comprised 3,786 adults, with a median age of 53.0 years and approximately 67.7% being male. The crucial control group consisted of 3,395 individuals who met the stringent criteria for HGNS candidacy but did not receive the implant. These criteria included a verified diagnosis of moderate to severe OSA through a sleep study and documented non-adherence to PAP therapy.

The propensity matching technique was vital in ensuring that the two groups were as comparable as possible at baseline. This statistical method aimed to balance the groups across numerous covariates, including demographic factors, the presence and severity of comorbidities, prior cardiovascular history, and the duration of their established OSA diagnosis. The "index year" was also considered, referring to the year the patient either received HGNS or was identified as a control.

HGNS was modeled as a time-varying covariate. This sophisticated approach allowed researchers to differentiate the potential effects of the treatment occurring within the first two years after implantation from those observed beyond the two-year mark. This temporal distinction is critical for understanding the evolving nature of HGNS’s impact on cardiovascular health.

Detailed Analysis of Cardiovascular Event Incidence

The detailed breakdown of findings provides further insight into the temporal dynamics of HGNS’s influence:

  • Diabetes and Hypertension in HGNS-Eligible Patients Without Baseline CVD:

    • Within two years of HGNS implantation, there was no statistically significant association with a new diagnosis of diabetes (HR 1.06; 95% CI 0.61 to 1.85). This suggests that HGNS does not immediately increase the risk of developing diabetes in this population.
    • However, after the two-year mark, HGNS was associated with a substantially lower hazard of diabetes diagnosis (HR 0.19; 95% CI 0.09 to 0.38). This points towards a potential long-term benefit in glucose metabolism or reduced incidence of type 2 diabetes.
    • Conversely, within the first two years, HGNS was associated with a higher hazard of developing hypertension (HR 1.70; 95% CI 1.26 to 2.28). This could be attributed to physiological adjustments or stress related to the implant and surgical procedure.
    • Beyond two years, the hazard of hypertension diagnosis significantly decreased (HR 0.49; 95% CI 0.33 to 0.73), suggesting a normalization or even improvement in blood pressure regulation over time.

  • Cardiovascular Events in Patients with Baseline Diabetes or Hypertension:

    • For individuals already managing diabetes or hypertension, the initial two years following HGNS implantation were associated with an increased risk of both minor cardiovascular events (HR 1.44; 95% CI 1.06 to 1.95) and major cardiovascular events (HR 1.62; 95% CI 1.06 to 2.48). This finding underscores the importance of careful patient selection and close monitoring in the early post-operative period for individuals with pre-existing cardiovascular risk factors.

  • Long-Term Trends in Cardiovascular Events:

    • While the overall hazard ratios for minor and major cardiovascular events after two years did not reach statistical significance, the trend analysis using time-varying models provided compelling evidence of a potential protective effect. The decreasing hazards for both minor (HR 0.42; 95% CI 0.22 to 0.79) and major (HR 0.40; 95% CI 0.17 to 0.93) cardiovascular events after two years strongly suggest that HGNS may contribute to a reduction in the incidence of these serious outcomes over extended periods.

Limitations and the Path Forward

The researchers acknowledge several limitations inherent in their study, which is crucial for interpreting the findings responsibly. These include:

  • Missing Data on OSA Severity: The administrative claims data did not consistently capture the precise severity of OSA for all patients, which is a critical factor influencing cardiovascular risk.
  • Absence of Cardiovascular Markers: Detailed laboratory values and other specific cardiovascular markers were not available, limiting the ability to fully assess physiological changes.
  • Race/Ethnicity Information: The dataset lacked comprehensive information on race and ethnicity, which can be important determinants of cardiovascular disease risk and treatment response.
  • Potential for Confounding and Surveillance Bias: As with any retrospective claims-based study, there is a possibility of residual confounding (unmeasured factors influencing outcomes) and surveillance bias (where patients receiving a new treatment might be more closely monitored, leading to earlier detection of events).

Despite these limitations, the study’s robust methodology, large sample size, and propensity matching approach lend significant weight to its conclusions. The observed patterns, characterized by an initial increase in risk followed by a potential long-term benefit, suggest that HGNS may offer a delayed but significant cardiovascular advantage.

Broader Implications and Future Research

The findings of this study have several important implications for clinicians and patients managing OSA. Firstly, they reinforce the understanding that OSA is a significant cardiovascular risk factor and that effective treatment is paramount. Secondly, while PAP therapy remains the first-line option, HGNS presents a viable alternative for a subset of patients. The study’s results suggest that while caution is warranted in the immediate post-operative period, particularly for those with existing cardiovascular disease, the long-term cardiovascular benefits of HGNS may be substantial.

This research underscores the need for continued investigation into the complex interplay between OSA, its treatments, and cardiovascular health. Future research should aim to:

  • Conduct prospective, randomized controlled trials: These trials are the gold standard for establishing causality and can provide more definitive answers regarding HGNS’s cardiovascular effects.
  • Incorporate detailed physiological monitoring: Measuring blood pressure, heart rate variability, inflammatory markers, and other relevant physiological parameters in real-time would offer a deeper understanding of the mechanisms at play.
  • Longer follow-up periods: Extending the follow-up beyond two years would be crucial to fully elucidate the long-term cardiovascular benefits suggested by the current study’s trend analyses.
  • Investigate patient subgroups: Further analysis could explore whether HGNS has differential effects based on specific patient characteristics, such as age, sex, comorbidities, and OSA severity.

In conclusion, this large-scale administrative claims study provides valuable real-world evidence suggesting that hypoglossal nerve stimulation, while associated with an initial increase in cardiovascular risk, may offer significant longer-term benefits for certain cardiovascular risk factors and potentially for cardiovascular event incidence. However, the variability in observed outcomes and the study’s limitations necessitate further confirmatory research to solidify these findings and guide clinical decision-making. The journey to fully understand the cardiovascular impact of HGNS is ongoing, but this study marks a significant step forward in that critical endeavor.